The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib.
X. Hu
No relevant relationships to disclose
L. P. Wang
No relevant relationships to disclose
Q. L. Zhang
No relevant relationships to disclose
J. Zhang
No relevant relationships to disclose
H. Y. Guo
No relevant relationships to disclose
S. Sun
No relevant relationships to disclose
B. Y. Wang
No relevant relationships to disclose
Z. Jia
No relevant relationships to disclose
Z. M. Shao
No relevant relationships to disclose
Z. H. Wang
No relevant relationships to disclose